Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Journal of Diabetes: Ushering in Volume 10
Zachary Bloomgarden
, Guang Ning
Icahn School of Medicine at Mount Sinai
Medicine
Medicine - Endocrinology, Diabetes and Bone Disease
Research output
:
Contribution to journal
›
Editorial
3
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Journal of Diabetes: Ushering in Volume 10'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Diabetes
100%
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
100%
Hemoglobin A1c (HbA1c)
66%
A1 Receptor
66%
Glucagon-like
66%
Receptor Agonist
66%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
66%
Thiazolidinediones
66%
Obesity
33%
Diabetic Nephropathy
33%
Adverse Effects
33%
Cardiovascular Disease
33%
Malignancy
33%
Treatment Modalities
33%
Fat Distribution
33%
Treatment Strategy
33%
Diabetes Management
33%
Insulin
33%
Clinical High Risk
33%
Epidemiologic
33%
Impact Factor
33%
Shock
33%
Dyslipidemia
33%
Cardiovascular Outcomes
33%
Psychosocial Factors
33%
High Cardiovascular Risk
33%
Diabetic Retinopathy
33%
Secretory Activity
33%
Transport Inhibitors
33%
Cost Issue
33%
Herbal Treatment
33%
Development Progress
33%
Sulfonylurea
33%
Glucagon-like peptide-1 Receptor (GLP-1R)
33%
Diabetic Neuropathy
33%
Small Step
33%
Sleep Abnormalities
33%
Adherence Factors
33%
Article Downloads
33%
Nursing and Health Professions
Cardiovascular Risk
100%
Hemoglobin A1c
50%
Thiazolidinedione
50%
Glucagon Like Peptide 1 Receptor Agonist
50%
Infection
25%
Patient Social Context
25%
Dyslipidemia
25%
Diabetic Nephropathy
25%
Diabetic Retinopathy
25%
Cardiovascular Condition
25%
Cotransporter
25%
Sulfonylurea
25%
Diabetic Neuropathy
25%
Adherence
25%
Medicine and Dentistry
Diabetes
100%
Cardiovascular Risk
57%
Cardiovascular System
42%
Hemoglobin A1c
28%
Glucagon-Like Peptide-1 Agonist
28%
Thiazolidinedione
28%
Health Care Cost
14%
Cancer
14%
Dyslipidemia
14%
Infection
14%
Diabetic Nephropathy
14%
Cardiovascular Condition
14%
Patient Social Context
14%
Diabetic Retinopathy
14%
Cotransporter
14%
Diabetic Neuropathy
14%
Sulfonylurea
14%
Adverse Effect
14%
Treatment Modality
14%
Pharmacology, Toxicology and Pharmaceutical Science
Cardiovascular Risk
100%
Glucagon Like Peptide 1 Receptor Agonist
50%
Hemoglobin A1c
50%
Thiazolidinedione
50%
Dyslipidemia
25%
Infection
25%
Diabetic Nephropathy
25%
Diabetic Retinopathy
25%
Cotransporter
25%
Herbal Treatment
25%
Sulfonylurea
25%
Diabetic Neuropathy
25%